Bioinfo-pharmacology: the example of therapeutic hypothermia

Fei Liu[1,2,3,#]; Xiangkang Jiang[1,2,3], Mao Zhang[1,2,3,*]

Author affiliations:

1. Department of Emergency Medicine, Second Affiliated Hospital of Zhejiang University, Hangzhou 310009, Zhejiang Province, China.

2. Institute of Emergency Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.

3. Key Laboratory of The Diagnosis and Treatment of Severe Trauma and Burn of Zhejiang Province, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.

[#] The first 1 author is the first author.

* corresponding author: Prof. Mao Zhang

Email: z2jzk@zju.edu.cn

Telephone: +86 13757119125

Declaration

Ethics approval and consent to participate.

Not applicable.

Consent for publication

All authors allow the publication of this article.

Availability of data and materials

All the data that support the findings of this study are available for email from authors.

Competing interests

The authors have declared that they have no conflicts or interests.

Funding

The authors have stated that no such relationships exist.

Authors' contributions

FL designed the research and wrote the article. XJ drew the pictures. ZM modified the article and analyzed the data.

Acknowledge

We thank Zaizai Cao, Xiangjie Lin, and Yuanyuan Hao for the algorithm discussion.

Abstract

Computer-aided drug discovery (CADD) is a widely used method for drug discovery with many successes. Meanwhile, CADD has the limitation of analyzing multi-level scores such as docking results of multiple proteins with multiple drugs. We propose a method of PageRank to solve the problem. This method can make a comprehensive ranking based on multi-level scores. Then we take an example of therapeutic hypothermia (TH). Three levels of TH data were used in the article: the log2 foldchange (logFC) of proteins, the relative expression values of mRNA, and the docking scores of proteins and molecules. After calculation, we get the comprehensive drug rank and drug combination rank of each group of TH, which means we can generate the rank of drug directly from bioinformatics. Based on this method, we raised the concept of bioinfo-pharmacology. Given the high rationality and compatibility of bioinfo-pharmacology, it can effectively enhance popular drug discovery techniques such as the docking or pharmacophore model. Besides, it could advance the application of precision medicine.

Keywords: computer-aided drug discovery (CADD); precision medicine; Therapeutic hypothermia; virtual screening;

Introduction

Drug discovery is an expensive and time-demanding process that faces many challenges, including low hit discovery rates for high-throughput screening, among many others.[1,2] Methods of computer-aided drug discovery (CADD) can significantly speed up the pace of such screening and reduce the cost. Until now, CADD has achieved important results. [3–5]

Meanwhile, CADD also has limitations. Researchers can only get the best match for a particular target (drug development), or the best match for a particular molecule (network pharmacology[6]). As a result, most pharmacological studies currently work on a single target. However, according to bioinformatics databases, diseases/treatments exist multiple targets, which generate complex regulation functions, in the different stages of diseases/treatments.[7]

Take therapeutic hypothermia as an example. Therapeutic hypothermia (TH) can limit the degree of some kinds of injuries in randomized trials[8] and animal experiments[9], and is even the only effective method for some diseases especially hypoxic-ischemic encephalopathy (HIE). HIE often causes severe neurological sequelae, which is the main reason for the poor prognosis of patients with stroke, shock, carbon monoxide poisoning, cerebral hemorrhage, and cardiac arrest.[10–12]

In the research based on TH, cold shock proteins especially cold-induced RNA binding protein (CIRP) show high expression [13] and rapid response [14]. CIRP has been shown to promote the translation of genes involved in DNA repair [15,16], telomerase maintenance[17], and genes associated with the translational machinery[18].

However, if CIRP leaks to the intercellular substance with cell swelling and rupture, it will become a harmful protein. Extracellular CIRP (eCIRP) showed a strong pro-inflammatory effect, leading to a heavier hypoxic injury.[19,20] Because of the habit of clinical medication, we cannot determine whether there are drugs that affect the therapeutic effect before and after the beginning of TH.

With the development of protein prediction technologies, especially AlphaFold2[21]

and RoseTTAFold[22], we can obtain the three-dimensional structure of proteins more quickly and accurately. All target proteins' structures can be predicted, and their best antagonists can be obtained by molecular docking. However, there is no technology for comprehensively ranking the cross-level data of numerical evaluation. To solve the complex function differences by temporal and spatial distribution differences of proteins, we use personalization-weight-PageRank to rank drugs targeting proteins predicted by AlphaFold2 and RoseTTAFold at different groups to predict the best drugs or drug combinations for each group. Based on these, we came up with the concept of bioinfo-pharmacology.

Method

Experiment design

As shown in Figure 1, the representative experiment of bioinfo-pharmacology is divided into 5 processes: 1. Protein or mRNA chosen by bioinformatics analysis; 2. Protein and drugs 3D structure acquisition and prediction; 3. Proteins' active sites prediction; 4. Drug/molecular group evaluation with target proteins; 5. PageRank of docking results, protein logFC, and mRNA expression. The experiment of animals or cells is referred by authors, but not forced. The biggest difference from previous studies is PageRank.

The data source of bioinformatics analysis

We retrieved the original data of mRNA expression under hypothermia treatment from the website of The National Center for Biotechnology Information (NCBI) (GSE54229). The research was reported by Sten et.al.[14] In their research, mouse embryonic fibroblasts were exposed to mild hypothermia (32°C) or normothermia (37°C) to gain the transcription response induced by hypothermia.

Expression Profile Analysis

The log2 fold-change (log2FC) and p-value were calculated for the normothermia group. Top 3 log2FC mRNA with q-value < 0.05 were selected from each group to enter the next step. If there exists mRNA with failed protein structure prediction, the mRNA would be skipped.

R 3.6.1 was used to detect differential expressed compared to matched normothermia samples. The clustering of genes was calculated by the "dist" and "hclust" function of R. The visualization of gene expression and clustering is performed by the "dendextend" package.

3D Data of proteins and small molecular drugs

All proteins were first searched on PubMed to see if there was protein clipping like

cleaved caspase-3[23].

Then the 3D structures of proteins were firstly searched from Protein Data Bank

(PDB), which is used for biological-related ligand-protein interaction. In this article,

no protein structure is listed on the PDB website. All the protein structures were

predicted by AlphaFold2 and RoseTTAFold.

AlphaFold2 is developed by Google and is the champion of the 14th Critical

Assessment of Structure Prediction (CASP14). In August 2021, AlphaFold submitted

a structure prediction database for all proteins. RoseTTAFold is based on the Rosetta

software which is designed for macromolecular modeling, docking, and design[24]

RoseTTAFold also has good application[25] in the research of protein structure

prediction. Finally, protein structures with fewer irregular regions will be selected for

the next step.

The 3D structures of 8,697 drugs (DrugBank, 5.1.8) were downloaded from

DrugBank Online (https://go.drugbank.com/). Approved, experimental, nutraceutical,

and investigational drugs by Food and Drug Administration (FDA) are included. We

split each drug molecule into a PDBQT-format file and minimized the energy

separately for docking with proteins.

Visualize evolutionary conservation and active site prediction

Visualize evolutionary conservation was performed by the ConSurf server[26]. In a

typical ConSurf application, through BLASTed[27] against the UNIREF-90

database[28] and aligning using MAFFT[29], the evolutionarily conserved positions

are analyzed by the Rate4Site algorithm.

Then, the Consensus approach-D (COACH-D) [30] was used to predict the active site

of target proteins. The COACH-D use five different methods to predict the binding

sites of protein ligands. Four of these methods are COFAC-TOR[31], FINDSITE[32],

TM-SITE[33], and S-SITE[33]. These methods predict binding sites by matching the

query structure and sequence with the ligand-binding template in BioLiP[34], which

is a semi-manual functional database[35] based on the PDB.

Virtual screening of potential compounds

To evaluate the hit compounds obtained from DrugBank and calculate their

interaction and binding posture in the active site of target proteins, the molecular

docking method was carried out through QuickVina 2[36]. QuickVina 2 uses the

calculation of shape and electrostatic potential similarity of binding pockets to select

molecules, which may exhibit binding patterns like those of binding pockets.

3D files of target proteins were dehydrated, hydrogenated. Then proteins were saved

as PDBQT files using AutoDock. AutoDock assisted in assigning Gasteiger charges

and adding polar hydrogen atoms to both the proteins and the compounds.

Molecular dynamics simulation

The molecular dynamics (MD) simulation was performed by Gromacs[37]. Firstly, a

protein-drug complex was prepared, including adding hydrogenation and balancing

charge. Then, we add a solvent so that the target protein and drug small molecules are

coated. The forcefield was Chemistry at HARvard Macromolecular Mechanics 36

(CHARMm 36). The simulation time is set as 50ns for the speed of calculation. The

simulation temperature is 309.15K (36°C) and the pressure is 1 atm. Root mean

square deviation (RMSD) and root mean square fluctuation (RMSF) were calculated

based on the first frame.

Personalization-weight-PageRank

We use personalization-weight-PageRank to rank cross level data. PageRank is a

comprehensive rank algorithm designed by Google and named after Larry Page.[38] It

is one of the most famous ranking algorithms of network nodes based on Markov

process. PageRank has been applied in medical domains with success.[39,40]

Personalization and weight represent 3 different levels of score data. The weight of

PageRank allows all nodes to be initially assigned different weights/probabilities.[41]

In this article, the weights of rank were set to docking values of proteins and drugs.

The higher the docking value, the higher the connection rate of the complex.

Personalization of PageRank reinforces the connection intensity between the nodes, which makes the result more personalized and realistic[42]. In this article, personalization is influenced by protein functions. If the protein performs a negative influence such as promoting apoptosis, the personalization will be calculated by $2^{\wedge}$(fold change) to ensure they are more than 1. Meanwhile, if the protein plays a positive role in the group, the personalization will be set as 1/(fold change + 1) to less than 1. The personalization values of all the drugs are set to 0 to prevent iterations of the drugs themselves from going wrong.

The calculation process is like putting all proteins and all drugs in the solution, then simulating the connections between all proteins and drugs by calculation. The damping factor is set to 0.85 to simulate the metabolism of proteins and drugs.

The whole calculation is based on Python 3.8.10. The relating python libraries include NetworkX, Pandas, and NumPy. We use Pandas and NumPy to import all the docking data into a matrix for PageRank calculating. The protein expression value is then imported by the PageRank personalization parameter of NetworkX. Lastly, we can get a comprehensive ranking of drugs.

Prediction and Rank of combined pharmacotherapy

In addition to the comprehensive ranking of drugs, we also try to generate the rank of drug combinations. Similarly, the calculation places all drugs of combination and target proteins in a solution to bind free.

First, all drugs will be grouped according to the docking results of drugs in each combination. In this article, to reduce the amount of calculation, we selected the TOP20 drugs of each protein to include in the drug combination pool. Then, all the combinations were performed personalization-weight-PageRank against all protein targets. The sum of each score of all drugs in the combination is the final score of the combination. Lastly, we get the rank of combinations.

To make the distribution of combinations more clear, we propose drug-protein-

expression fit score (DPEFS) to show the data distribution pattern. The calculation is

as follows: The PageRank values of all proteins were summed by multiplying logFC,

then divided by the total PageRank values of drugs, and finally divided by the

PageRank values of specific proteins for standardized calculation. It is used for

standardized calculation for comparing different combinations.

DPEFS evaluates the combination by referring to the protein expression trend. The

higher the DPEFS, the better the fitness. In actual drug design, DPEFS is relatively

high and PageRank score is relatively low, indicating that drugs of combination are

relatively moderate, which suggests a negative outcome. All code can be found in

GitHub (https://github.com/FeiLiuEM/PageRank-weight-drug).

Result

Expression analysis and clustering of hypothermia

Figure 2 shows the expressions of different mRNA of different groups after hypothermia. From the inside to the outside, the rings were divided into hypothermia 0.5h group, hypothermia 1H group, hypothermia 2H group, hypothermia 4H group, hypothermia 8h group, and hypothermia 18h group.

As shown in Table 1, in each group, we selected the top 3 expression protein targets. In the Hypothermia 0.5h group, the target proteins are circadian-associated transcriptional repressor (CIART), Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1), and Uridine diphosphate glucose pyrophosphatase nudix hydrolase 22 (NUDT22). The target proteins of the Hypothermia 1h group are CHAC1, corneodesmosin (CDSN), and Nuclear receptor subfamily 1 group D member 1 (NR1D1). The target proteins of the Hypothermia 2h group are cold-induced RNA-binding protein (CIRP), armadillo repeat-containing X-linked protein 5 (ARMCX5), and coiled-coil domain-containing protein 122 (CCDC122). The target proteins of the Hypothermia 4h group are CIRP, receptor activity-modifying protein 3 (RAMP3), and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). The target proteins of the Hypothermia 4h group are the same: CIRP, RAMP3, and NAD(P)H dehydrogenase [quinone] 1 (NQO1). Within the targets, CHAC1 could enhance apoptosis[43]. NUDT22 is an Mg^{2+}-dependent UDP-glucose and UDP-galactose hydrolase[44], while high glucose shows a negative effect in HIE like stroke[45]. CCDC122 potentially pro-inflammatory[46]. CIRP can effectively reduce cell death in the early stage of hypothermia therapy. However, it has a strong pro-inflammatory effect outside the cell, leading to cell killing. There is no definitive research on the timing of this shift. Referring to the previous article[47], we conservatively believed that CIRP could be identified as a negative protein from the 8H group. CEACAM1[48] and NQO1[49] promote apoptosis. All the other targets are shown protective effects or don't have enough data. The personalization values were calculated in Table 1. All the structures of target

proteins in Figure 3 were obtained by the rules in the section of Materials and Methods.

Visualize evolutionary conservation and Structure-Function Relationship-Based Binding Site Prediction

The conservation analysis of all the target proteins was listed in Figure 4A-K. The redder the amino acid, the higher possibility the amino acid sequence with function. Then we identified its structure-function relationship by the COACH-D server. The results showed a familiar result of conservation analysis listed in Figure 4L-V. As shown in Table 2, the range around 3-5 Å of the active site was used for the setting of the receptor pocket of the target proteins that were used for virtual screening.

Virtual Screening of target proteins' Antagonists

We utilized the virtual screening technique to identify potential antagonists exhibiting an adequate binding affinity. We started with a chemical database consisting of 8,697 drug molecules and isolated a set of compounds satisfying the threshold of a high docking score. The results of the best match complexes are shown in Figure 5 and all the results are listed in the Additional file Table 1.

MD Simulations and Binding Free Energy Analysis

We performed MD simulation of 11 complexes to measure the stability of the protein-ligand complex. RMSD (root-mean-square deviation) profiles of the protein are shown in Figure 6A, which indicates that all systems were relatively stable during the entire simulation run. Moreover, RMSF profiles of protein are measured to evaluate the moving of each amino acid. All proteins are available for further analysis (Figure 6B).

The RMSD of drug atoms was also conducted to predict the stability of the atoms in docked complexes (Figure 6C). Most compounds exhibited a consistently low RMSD, suggesting that these compounds formed stable complexes.

Drug rank of TH in different groups

We rank all drugs by PageRank. First, we PageRank all the drugs and get the results

in table3. 2-drug-combinations are ranked in Table 4 and 3-drug-combinations in the

additional file Table 2. For comprehensive rank, the results of PageRank were listed.

For drug-combination ranks, the percentages of each drug's value in the combination

were calculated. And DPEFS was calculated for analyzing the distribution differences

of drug combinations.

Discussion

In this paper, a new pharmacological method — bioinfo-pharmacology is proposed, using therapeutic hypothermia as an example. By bioinformatics analysis, protein structure prediction, and PageRank, we provide a direct bridge between symptom/treatment and drug design.

AlphaFold2 and RoseTTAFold were used for protein structure prediction. And the number of proteins selected by AlphaFold2 in this research was close to that of RoseTTAFold. During the process of protein structure prediction, we found that for some proteins, the structures predicted by RoseTTAFold have less irregular structure than that of AlphaFold2. This may be due to the 2D distance map level transformed and integrated by RoseTTAFold during neural network training[22], while AlphaFold2 only paired structure database and genetic database. We also find a phenomenon that the predicted protein structures were relatively unstable under molecular dynamics simulation than preview reports of other protein structures detected by X-ray.

The application of PageRank is suitable. First, the combination of drug molecules is a memoryless stochastic process, which meets the qualifications of the Markov process. Second, our method aims to simulate the binding process in *vivo*. The comprehensive analysis involves free docking of proteins with all drugs. Drug combination analysis is to put proteins and related drugs into the solution for docking.

Besides, the method has good compatibility for the wide compatibility of PageRank. In theory, all the technologies with numerical results can be ranked by the method. In this paper, for the lack of bioinformatics data of Therapeutic hypothermia, we only do a basic analysis. If there is more data of the TH, the analysis of Weighted Gene Coexpression Network Analysis (WGCNA)[50] or Gene Regulatory Networks (GRN)[51] will be better because they could provide more plausible results of protein list.

Meanwhile, pharmacophore models[52] can use bioinfo-pharmacology for highly efficient drug design. After ranking, top-ranked pharmacophore fingerprints or

alignments could be linked together for good pharmacological effects. And ultimately, improve the therapeutic effect of drugs, reduce toxic and side effects, improve the success rate of clinical trials of new drugs, save drug research and development costs. For the same reason, this method can also enhance network pharmacology and chrono-pharmacology. Network pharmacology[6] focuses on the application of protein network structures to improve drug discovery. By PageRank, the association between protein network structures and different drugs can be more accurately understood through comprehensive drug analysis of multiple targets rather than the previous single target. Thus, it has a good promotion effect on traditional herbal medicine research. In traditional herbal medicine, there may be multiple drug molecules in a single herb, and its complex multi-target problem can be efficiently analyzed by new methods. Another influenced area is chrono-pharmacology. Chrono-pharmacology[53] is expert in the adaptation and anticipation mechanisms of the body concerning clock system regulation of various kinetic and dynamic pathways, including absorption, distribution, metabolism, and excretion of drugs and nutrients. By bioinfo-pharmacology, researchers can develop drugs for different time groups, which will bring precision medicine to this kind of diseases.

Based on these potential improvements and high compatibility, we propose the concept of bioinfo-pharmacology for its ability to directly apply bioinformatics for drug discovery. Bioinfo-pharmacology is a method that uses bioinformatics, protein structure prediction, and PageRank for drug design. The main feature is that multiple targets target multiple molecules/pharmacophores. Overall, this approach builds a bridge between disease/treatment and drug development, bringing up more possibilities for future drug development.

This research has some defects. 1: For the speed of calculating, we only choose the top 3 mRNAs and use the top 1 complex for MD simulation. Furthermore, the duration of molecular dynamics simulation is set to 50ns. These operations mitigate the rationality of the results relatively; 2. Theoretically, pharmacophore modeling has a better improvement under PageRank. But considering the purpose of the article, we

use AutoDock to dock all the marketing drugs.

In summary, this paper proposes a new method of pharmacology—bioinfo-

pharmacology by PageRank. The results provide medical clues for the treatment of

TH. Besides, it can help the functional research of proteins at the molecular level for

experimental biologists. In addition, we can do drug combination analysis of drugs

similarly. The new approach could have a huge impact on precision medicine, drug

design, and traditional herbal medicine in the future.

Reference

1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33.

2. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery: Principles of early drug discovery. Br J Pharmacol. 2011;162:1239–49.

3. Li R, Li Y, Liang X, Yang L, Su M, Lai KP. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets. Brief Bioinform. 2021;22:1279–90.

4. Gandasi NR, Yin P, Omar-Hmeadi M, Ottosson Laakso E, Vikman P, Barg S. Glucose-Dependent Granule Docking Limits Insulin Secretion and Is Decreased in Human Type 2 Diabetes. Cell Metab. 2018;27:470-478.e4.

5. Cypionka A, Stein A, Hernandez JM, Hippchen H, Jahn R, Walla PJ. Discrimination between docking and fusion of liposomes reconstituted with neuronal SNARE-proteins using FCS. Proc Natl Acad Sci U S A. 2009;106:18575–80.

6. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–90.

7. Wooller SK, Benstead-Hume G, Chen X, Ali Y, Pearl FMG. Bioinformatics in translational drug discovery. Biosci Rep. 2017;37:BSR20160180.

8. Lascarrou J-B, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, et al. Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm. N Engl J Med. 2019;381:2327–37.

9. Kim JY, Kim JH, Park J, Beom JH, Chung SP, You JS, et al. Targeted Temperature Management at 36 °C Shows Therapeutic Effectiveness via Alteration of Microglial Activation and Polarization After Ischemic Stroke. Transl Stroke Res. 2021;

10. Hosseini M, Wilson RH, Crouzet C, Amirhekmat A, Wei KS, Akbari Y. Resuscitating the Globally Ischemic Brain: TTM and Beyond. Neurother J Am Soc Exp Neurother. 2020;17:539–62.

11. Hazinski MF, Nolan JP, Aickin R, Bhanji F, Billi JE, Callaway CW, et al. Part 1: Executive Summary: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132:S2-39.

12. Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J, Chiche J-D, et al. Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. Intensive Care Med. 2013;39:1972–80.

13. Rosenthal L-M, Leithner C, Tong G, Streitberger KJ, Krech J, Storm C, et al. RBM3 and CIRP expressions in targeted temperature

management treated cardiac arrest patients-A prospective single center study. PloS One. 2019;14:e0226005.

14. Ilmjärv S, Hundahl CA, Reimets R, Niitsoo M, Kolde R, Vilo J, et al. Estimating differential expression from multiple indicators. Nucleic Acids Res. 2014;42:e72.

15. Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, Carrier F. Functional significance for a heterogenous ribonucleoprotein A18 signature RNA motif in the 3'-untranslated region of ataxia telangiectasia mutated and Rad3-related (ATR) transcript. J Biol Chem. 2010;285:8887–93.

16. Haley B, Paunesku T, Protić M, Woloschak GE. Response of heterogeneous ribonuclear proteins (hnRNP) to ionising radiation and their involvement in DNA damage repair. Int J Radiat Biol. 2009;85:643–55.

17. Zhang Y, Wu Y, Mao P, Li F, Han X, Zhang Y, et al. Cold-inducible RNA-binding protein CIRP/hnRNP A18 regulates telomerase activity in a temperature-dependent manner. Nucleic Acids Res. 2016;44:761–75.

18. Zhong P, Huang H. Recent progress in the research of cold-inducible RNA-binding protein. Future Sci OA. 2017;3:FSO246.

19. Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, et al. Stress response protein cirp links inflammation and tumorigenesis in colitis-associated cancer. Cancer Res. 2014;74:6119–28.

20. Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S, Watanabe T, et al. Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. Inflamm Bowel Dis. 2017;23:57–65.

21. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.

22. Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee GR, et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373:871–6.

23. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997;278:294–8.

24. Leman JK, Weitzner BD, Lewis SM, Adolf-Bryfogle J, Alam N, Alford RF, et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat Methods. 2020;17:665–80.

25. Humphreys IR, Pei J, Baek M, Krishnakumar A, Anishchenko I, Ovchinnikov S, et al. Computed structures of core eukaryotic protein complexes. Science. 2021;eabm4805.

26. Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et

al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 2016;44:W344-350.

27. Biegert A, Söding J. Sequence context-specific profiles for homology searching. Proc Natl Acad Sci U S A. 2009;106:3770–5.

28. Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt Consortium. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinforma Oxf Engl. 2015;31:926–32.

29. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30:772–80.

30. Wu Q, Peng Z, Zhang Y, Yang J. COACH-D: improved protein-ligand binding sites prediction with refined ligand-binding poses through molecular docking. Nucleic Acids Res. 2018;46:W438–42.

31. Roy A, Yang J, Zhang Y. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. Nucleic Acids Res. 2012;40:W471-477.

32. Brylinski M, Skolnick J. A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation. Proc Natl Acad Sci U S A. 2008;105:129–34.

33. Yang J, Roy A, Zhang Y. Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinforma Oxf Engl. 2013;29:2588–95.

34. Yang J, Roy A, Zhang Y. BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions. Nucleic Acids Res. 2013;41:D1096-1103.

35. Rose PW, Prlić A, Altunkaya A, Bi C, Bradley AR, Christie CH, et al. The RCSB protein data bank: integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 2017;45:D271–81.

36. Alhossary A, Handoko SD, Mu Y, Kwoh C-K. Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinforma Oxf Engl. 2015;31:2214–6.

37. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701–18.

38. Page L, Brin S, Motwani R, Winograd T. The PageRank Citation Ranking: Bringing Order to the Web. [Internet]. Stanford InfoLab; 1999 Nov. Report No.: 1999–66. Available from: http://ilpubs.stanford.edu:8090/422/

39. Kalecky K, Cho Y-R. PrimAlign: PageRank-inspired Markovian alignment for large biological networks. Bioinforma Oxf Engl. 2018;34:i537–46.

40. Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends

in the development of miRNA bioinformatics tools. Brief Bioinform. 2019;20:1836–52.

41. Xing W, Ghorbani A. Weighted PageRank algorithm. Proc Second Annu Conf Commun Netw Serv Res 2004. 2004. p. 305–14.

42. Haveliwala T, Kamvar S, Jeh G. An Analytical Comparison of Approaches to Personalizing PageRank [Internet]. Stanford; 2003 Jun. Report No.: 2003–35. Available from: http://ilpubs.stanford.edu:8090/596/

43. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ. CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol Baltim Md 1950. 2009;182:466–76.

44. Carter M, Jemth A-S, Carreras-Puigvert J, Herr P, Martínez Carranza M, Vallin KSA, et al. Human NUDT22 Is a UDP-Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold. Struct Lond Engl 1993. 2018;26:295-303.e6.

45. Zhang S, Zuo W, Guo X-F, He W-B, Chen N-H. Cerebral glucose transporter: the possible therapeutic target for ischemic stroke. Neurochem Int. 2014;70:22–9.

46. Leturiondo AL, Noronha AB, Mendonça CYR, Ferreira C de O, Alvarado-Arnez LE, Manta FS de N, et al. Association of NOD2 and IFNG single nucleotide polymorphisms with leprosy in the Amazon ethnic admixed population. PLoS Negl Trop Dis. 2020;14:e0008247.

47. Denning N-L, Yang W-L, Hansen L, Prince J, Wang P. C23, an oligopeptide derived from cold-inducible RNA-binding protein, suppresses inflammation and reduces lung injury in neonatal sepsis. J Pediatr Surg. 2019;54:2053–60.

48. Zhao C, Dang Z, Sun J, Yuan S, Xie L. Up-regulation of microRNA-30b/30d cluster represses hepatocyte apoptosis in mice with fulminant hepatic failure by inhibiting CEACAM1. IUBMB Life. 2020;72:1349–63.

49. Feng Y, Cui R, Li Z, Zhang X, Jia Y, Zhang X, et al. Methane Alleviates Acetaminophen-Induced Liver Injury by Inhibiting Inflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and Apoptosis through the Nrf2/HO-1/NQO1 Signaling Pathway. Oxid Med Cell Longev. 2019;2019:7067619.

50. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

51. Alexiou A, Chatzichronis S, Perveen A, Hafeez A, Ashraf GM. Algorithmic and Stochastic Representations of Gene Regulatory Networks and Protein-Protein Interactions. Curr Top Med Chem. 2019;19:413–25.

52. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2014;66:334–95.

53. Tahara Y, Shibata S. Chrono-biology, chrono-pharmacology, and

545   **chrono-nutrition. J Pharmacol Sci. 2014;124:320–35.**

547 Table 1. The target proteins of different groups.

Group	Target	logFC	Personalization
	CIART	0.46	0.42
0.5h	CHAC1	0.43	1.34
	NUDT22	0.40	1.32
	CDSN	0.52	0.41
1h	NR1D1	0.50	0.41
	CHAC1	0.50	1.41
	CIRP	0.80	0.36
2h	ARMCX5	0.66	0.39
	CCDC122	0.49	1.41
	CIRP	1.17	0.31
4h	RAMP3	0.91	0.35
	CEACAM1	0.87	1.82
	CIRP	1.57	2.97
8h	RAMP3	1.33	0.28
	NQO1	1.18	2.27
	CIRP	1.71	3.27
18h	NQO1	1.55	2.93
	RAMP3	1.32	0.29

552   Table 2. The docking parameters of target proteins.

Protein name	protein source	X	Y	Z	LEN-X	LEN-Y	LEN-Z
ARMCX5	RoseTTAFold	-7.06	31.20	-43.05	29.25	28.50	24.75
CDSN	RoseTTAFold	51.80	53.51	31.17	39.75	20.25	21.00
CEACAM1	AlphaFold2	-41.13	3.42	5.67	39.75	22.50	22.50
CHAC1	AlphaFold2	-3.04	-0.53	0.22	23.25	25.50	35.25
CIART	RoseTTAFold	36.79	-16.59	-36.23	28.50	38.25	22.50
CIRP	RoseTTAFold	14.48	2.86	-9.56	17.25	15.00	19.50
NQO1	AlphaFold2	-1.86	-16.32	-9.20	29.25	29.25	28.50
NR1D1	RoseTTAFold	0.34	35.70	10.28	39.75	25.50	24.75
NUDT22	AlphaFold2	10.08	-12.04	14.09	17.25	38.25	22.50
RAMP3	AlphaFold2	0.00	-10.93	-5.29	24.00	24.00	21.00
CCDC122	RoseTTAFold	119.27	23.34	8.09	36.00	47.25	47.25

556 Table 3. The comprehensive rank of drugs at different groups.

Group	Drug	weighted_personalized_PageRank (*10^-4)
h0.5h	Fluzoparib	0.81
	Lorecivivint	0.80
	Vactosertib	0.80
h1h	Lorecivivint	0.81
	AC-430	0.81
	Raltegravir	0.80
h2h	Phthalocyanine	0.90
	Vazegepant	0.87
	Bemcentinib	0.86
h4h	Phthalocyanine	0.85
	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	0.84
	Bemcentinib	0.84
h8h	Phthalocyanine	0.87
	MK-3207	0.86
	Lifirafenib	0.85
h18h	Phthalocyanine	0.87
	MK-3207	0.86
	Lifirafenib	0.85

Table 4. Rank of 2 drug combinations of different group.

	drug1	drug2	PageRank value of drug1	per-sentage	PageRank value of drug2	per-sentage	personal-ized_weight_PageRank	Drug-pro-tein-expres-sion fit score
	Lorecivivint	Fluzoparib	0.41	49.85	0.42	50.15	0.83	2.30
h0.5h	Vactosertib	Fluzoparib	0.41	49.56	0.42	50.44	0.83	2.33
	2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate)	Fluzoparib	0.41	49.68	0.42	50.32	0.83	2.32
	Lorecivivint	AC-430	0.41	49.67	0.42	50.33	0.83	4.36
h1h	Lorecivivint	Raltegravir	0.42	50.12	0.41	49.88	0.83	4.40
	Lorecivivint	Vactosertib	0.42	50.21	0.41	49.79	0.83	4.37
	Phthalocyanine	Vazegepant	0.42	51.42	0.40	48.58	0.82	4.65
h2h	Phthalocyanine	Bemcentinib	0.43	51.84	0.40	48.16	0.82	4.71
	Phthalocyanine	Lifirafenib	0.43	52.28	0.39	47.72	0.82	4.64
h4h	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROME-THYL)PHENYL]BENZAMIDE	CD564	0.41	50.25	0.41	49.75	0.82	1.60

	Adapalene	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROME-THYL)PHENYL]BENZAMIDE	0.41	49.90	0.41	50.10	0.82	1.60
	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROME-THYL)PHENYL]BENZAMIDE	Phthalocyanine	0.42	50.52	0.41	49.48	0.82	1.60
h8h	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	3.94
	Phthalocyanine	Lifirafenib	0.42	50.17	0.41	49.83	0.83	3.93
	Lifirafenib	MK-3207	0.41	49.75	0.42	50.25	0.83	3.94
h18h	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	4.95
	Lifirafenib	MK-3207	0.41	49.77	0.42	50.23	0.83	4.95
	Phthalocyanine	Lifirafenib	0.42	50.14	0.41	49.86	0.83	4.94

Figure 1. Representative workflow for bioinfo-pharmacology drug design.

14 Figure 2. Circular visualization of expression patterns and clustering of hypothermia

15 treatment. Red indicates gene upregulation and blue indicates downregulation.

Figure 3. The 3D structures of target proteins. A. ARMCX5; B. CCDC; C. CDSN; D. CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J. NUDT22; K. RAMP3.

Figure 4. The ConSurf analysis and predicted active sites of target proteins. The upper 11 pictures are ConSurf analysis results. The last 11 pictures are predicted active sites. A&L. ARMCX5; B&M. CCDC; C&N. CDSN; D&O. CEACAM1; E&P. CHAC1; F&Q. CIART; G&R. CIRP; H&S. NQO1; I&T. NR1D1; J&U. NUDT22; K&V. RAMP3. The redder the amino acid, the more conservative it is. The greener the color, the less conservative it is.

63 Figure 5. The best docking molecular for each protein. A. ARMCX5; B. CCDC; C.

64 CDSN; D. CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J.

65 NUDT22; K. RAMP3.

Figure 6. The RMSD and RMSF of MD simulation. A. The RMSD of proteins. B. The RMSF of proteins. C. The RMSD of each molecular of proteins.